<p>Corient Private Wealth LLC 在最近向證券交易委員會提交的文件中表示，在第二季度將其在 Moderna, Inc.（NASDAQ:MRNA - 免費報告）股票中的持股比例提高了 155.8%。該基金在季度內額外購買了 34,354 股後，持有 56,400 股公司的股票。截至其最近的 SEC 文件，Corient Private Wealth LLC 在 Moderna 的持股價值為 1,537,000 美元。</p>
<ul>
<li>Moderna 股票看起來適合進行空頭擠壓</li>
</ul>
<p>其他幾家對沖基金和機構投資者最近也增加或減少了對 MRNA 的持股。Osaic Holdings Inc.在第二季度將其在 Moderna 的持股增加了 7.0%。Osaic Holdings Inc.現在擁有 46,709 股公司的股票，價值 1,289,000 美元，此前在上個季度又購買了 3,065 股。Thrivent Financial for Lutherans 在第二季度將其在 Moderna 的持股提高了 600.7%。Thrivent Financial for Lutherans 現在擁有 92,999 股公司的股票，價值 2,566,000 美元，此前在上個季度又購買了 79,726 股。Marex Group plc 在第二季度獲得了 Moderna 的新股份，價值 359,000 美元。懷俄明州也在第二季度獲得了 Moderna 的新股份，價值 94,000 美元。最後，Hudson Bay Capital Management LP 在第二季度將其在 Moderna 的持股提高了 108.4%。Hudson Bay Capital Management LP 現在擁有 75,000 股公司的股票，價值 2,069,000 美元，此前在上個季度又購買了 39,020 股。機構投資者和對沖基金持有公司 75.33% 的股票。</p>
<h2>Moderna 股票表現</h2>
<p>NASDAQ MRNA 的股票在週四開盤價為 32.73 美元。該股票的市值為 127.9 億美元，市盈率為-4.06，貝塔值為 1.11。Moderna, Inc.的 52 周低點為 22.28 美元，52 周高點為 48.92 美元。該股票的 50 日移動平均價格為 26.78 美元，200 日移動平均價格為 27.33 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 03/10 - 03/14</li>
</ul>
<p>Moderna（NASDAQ:MRNA - 獲取免費報告）最近在 11 月 6 日（星期四）發佈了季度財報。公司報告季度每股收益（EPS）為（0.51 美元），超出分析師一致預期的（2.15 美元）1.64 美元。Moderna 的股本回報率為-29.81%，淨利潤率為-139.61%。該業務在季度內的收入為 10.2 億美元，而分析師預期為 8.9329 億美元。去年同期，公司每股收益為 0.03 美元。Moderna 的季度收入同比下降了 45.4%。作為一個整體，研究分析師預測 Moderna, Inc.在當前年度將發佈-9.61 的每股收益。</p>
<h2>Moderna 的內部買賣</h2>
<p>在其他新聞中，董事 Noubar Afeyan 在 12 月 11 日（星期四）以 29.48 美元的平均價格出售了 23,853 股股票，總價值為 703,186.44 美元。交易完成後，該董事持有 3,924 股公司的股票，價值約 115,679.52 美元。這代表了他們持股比例的 85.87% 的減少。該交易已在向證券交易委員會的法律文件中披露，可以通過 SEC 網站訪問。目前 10.90% 的股票由公司內部人士持有。</p>
<h2>分析師設定新目標價</h2>
<ul>
<li>Moderna：首席執行官剛剛購買 500 萬美元股票的 4 個關鍵原因</li>
</ul>
<p>幾家研究公司最近對 MRNA 發佈了報告。Weiss Ratings 在 10 月 8 日（星期三）重申了對 Moderna 股票的 “賣出（e+）” 評級。Leerink Partners 將 Moderna 的目標價格從 15.00 美元上調至 18.00 美元，並在 11 月 21 日（星期五）的研究報告中給予公司 “表現不佳” 的評級。花旗集團將 Moderna 的目標價格從 30.00 美元下調至 28.00 美元，並在 10 月 23 日（星期四）的研究報告中為公司設定了 “中性” 評級。摩根士丹利在 12 月 12 日（星期五）的報告中將 Moderna 的目標價格從 30.00 美元下調至 28.00 美元，並對該股票設定了 “同等權重” 的評級。最後，Needham &amp; Company LLC 在 10 月 20 日（星期一）的研究報告中重申了對 Moderna 的 “持有” 評級。兩位分析師對該股票給予了買入評級，十二位分析師給予了持有評級，五位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “減持”，平均目標價格為 29.21 美元。</p>
<p><strong>獲取我們對 Moderna 的最新分析</strong></p>
<h2>Moderna 公司簡介</h2>
<p>（免費報告）</p>
<p>Moderna, Inc.是一家總部位於馬薩諸塞州劍橋的生物技術公司，專注於信使 RNA（mRNA）治療和疫苗。該公司的平台利用合成 mRNA 指示細胞產生可以預防或治療疾病的蛋白質。自 2010 年成立以來，Moderna 已從早期研究發展到一系列旨在應對傳染病、罕見遺傳疾病和慢性疾病的疫苗和治療候選產品。</p>
<p>Moderna 的旗艦產品是其基於 mRNA 的 COVID-19 疫苗，這是首個獲得緊急使用授權並在多個司法管轄區獲得完全批准的疫苗。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票超過 Moderna</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “3 美元 AI 奇蹟股票” 即將爆發</li>
<li>任何費用可以從資本利得税中扣除嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘記 AI，這將是下一個重大科技突破</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Moderna 嗎？</h2>
<p>在你考慮 Moderna 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Moderna 並不在名單上。</p>
<p>雖然 Moderna 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MRNA

<p>Corient Private Wealth LLC 在第二季度將其在 Moderna, Inc. 的持股增加了 155.8%，目前持有 56,400 股，價值 154 萬美元。分析師對 Moderna 的評級褒貶不一，普遍評級為 “減持”，平均目標價為 29.21 美元。機構投資者持有該股票的 75.33%，最近的內部交易包括董事 Noubar Afeyan 的一筆重大出售</p>

<p>Corient Private Wealth LLC boosted its stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 155.8% during the second quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 56,400 shares of the company's stock after acquiring an additional 34,354 shares during the quarter. Corient Private Wealth LLC's holdings in Moderna were worth $1,537,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Corient Private Wealth LLC 在最近向證券交易委員會提交的文件中表示，在第二季度將其在 Moderna, Inc.（NASDAQ:MRNA - 免費報告）股票中的持股比例提高了 155.8%。該基金在季度內額外購買了 34,354 股後，持有 56,400 股公司的股票。截至其最近的 SEC 文件，Corient Private Wealth LLC 在 Moderna 的持股價值為 1,537,000 美元。</p>
</div><ul>
<li>Moderna Stock Looks Ripe for a Short Squeeze</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna 股票看起來適合進行空頭擠壓</li>
</ul>
</div><p>Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. Osaic Holdings Inc. increased its holdings in shares of Moderna by 7.0% in the second quarter. Osaic Holdings Inc. now owns 46,709 shares of the company's stock valued at $1,289,000 after purchasing an additional 3,065 shares in the last quarter. Thrivent Financial for Lutherans boosted its position in Moderna by 600.7% in the 2nd quarter. Thrivent Financial for Lutherans now owns 92,999 shares of the company's stock valued at $2,566,000 after buying an additional 79,726 shares during the last quarter. Marex Group plc acquired a new stake in shares of Moderna in the 2nd quarter valued at $359,000. State of Wyoming acquired a new stake in shares of Moderna in the 2nd quarter valued at $94,000. Finally, Hudson Bay Capital Management LP raised its position in shares of Moderna by 108.4% during the second quarter. Hudson Bay Capital Management LP now owns 75,000 shares of the company's stock worth $2,069,000 after acquiring an additional 39,020 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金和機構投資者最近也增加或減少了對 MRNA 的持股。Osaic Holdings Inc.在第二季度將其在 Moderna 的持股增加了 7.0%。Osaic Holdings Inc.現在擁有 46,709 股公司的股票，價值 1,289,000 美元，此前在上個季度又購買了 3,065 股。Thrivent Financial for Lutherans 在第二季度將其在 Moderna 的持股提高了 600.7%。Thrivent Financial for Lutherans 現在擁有 92,999 股公司的股票，價值 2,566,000 美元，此前在上個季度又購買了 79,726 股。Marex Group plc 在第二季度獲得了 Moderna 的新股份，價值 359,000 美元。懷俄明州也在第二季度獲得了 Moderna 的新股份，價值 94,000 美元。最後，Hudson Bay Capital Management LP 在第二季度將其在 Moderna 的持股提高了 108.4%。Hudson Bay Capital Management LP 現在擁有 75,000 股公司的股票，價值 2,069,000 美元，此前在上個季度又購買了 39,020 股。機構投資者和對沖基金持有公司 75.33% 的股票。</p>
</div><h2>Moderna Stock Performance</h2>
<div class="lb-trans"><h2>Moderna 股票表現</h2>
</div><p>Shares of NASDAQ MRNA opened at $32.73 on Thursday. The stock has a market capitalization of $12.79 billion, a PE ratio of -4.06 and a beta of 1.11. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $48.92. The stock has a 50 day moving average price of $26.78 and a 200 day moving average price of $27.33.</p>
<div class="lb-trans"><p>NASDAQ MRNA 的股票在週四開盤價為 32.73 美元。該股票的市值為 127.9 億美元，市盈率為-4.06，貝塔值為 1.11。Moderna, Inc.的 52 周低點為 22.28 美元，52 周高點為 48.92 美元。該股票的 50 日移動平均價格為 26.78 美元，200 日移動平均價格為 27.33 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 03/10 - 03/14</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 03/10 - 03/14</li>
</ul>
</div><p>Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($2.15) by $1.64. Moderna had a negative return on equity of 29.81% and a negative net margin of 139.61%.The business had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $893.29 million. During the same quarter last year, the company posted $0.03 earnings per share. Moderna's quarterly revenue was down 45.4% on a year-over-year basis. As a group, research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.</p>
<div class="lb-trans"><p>Moderna（NASDAQ:MRNA - 獲取免費報告）最近在 11 月 6 日（星期四）發佈了季度財報。公司報告季度每股收益（EPS）為（0.51 美元），超出分析師一致預期的（2.15 美元）1.64 美元。Moderna 的股本回報率為-29.81%，淨利潤率為-139.61%。該業務在季度內的收入為 10.2 億美元，而分析師預期為 8.9329 億美元。去年同期，公司每股收益為 0.03 美元。Moderna 的季度收入同比下降了 45.4%。作為一個整體，研究分析師預測 Moderna, Inc.在當前年度將發佈-9.61 的每股收益。</p>
</div><h2>Insider Buying and Selling at Moderna</h2>
<div class="lb-trans"><h2>Moderna 的內部買賣</h2>
</div><p>In other news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the transaction, the director owned 3,924 shares of the company's stock, valued at approximately $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. 10.90% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Noubar Afeyan 在 12 月 11 日（星期四）以 29.48 美元的平均價格出售了 23,853 股股票，總價值為 703,186.44 美元。交易完成後，該董事持有 3,924 股公司的股票，價值約 115,679.52 美元。這代表了他們持股比例的 85.87% 的減少。該交易已在向證券交易委員會的法律文件中披露，可以通過 SEC 網站訪問。目前 10.90% 的股票由公司內部人士持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><ul>
<li>Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares</li>
</ul>
<div class="lb-trans"><ul>
<li>Moderna：首席執行官剛剛購買 500 萬美元股票的 4 個關鍵原因</li>
</ul>
</div><p>Several research firms recently issued reports on MRNA. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Moderna in a report on Wednesday, October 8th. Leerink Partners upped their target price on shares of Moderna from $15.00 to $18.00 and gave the company an &#34;underperform&#34; rating in a research report on Friday, November 21st. Citigroup lowered their price target on shares of Moderna from $30.00 to $28.00 and set a &#34;neutral&#34; rating for the company in a research report on Thursday, October 23rd. Morgan Stanley cut their price objective on shares of Moderna from $30.00 to $28.00 and set an &#34;equal weight&#34; rating on the stock in a report on Friday, December 12th. Finally, Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of Moderna in a research note on Monday, October 20th. Two analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Reduce&#34; and an average target price of $29.21.</p>
<div class="lb-trans"><p>幾家研究公司最近對 MRNA 發佈了報告。Weiss Ratings 在 10 月 8 日（星期三）重申了對 Moderna 股票的 “賣出（e+）” 評級。Leerink Partners 將 Moderna 的目標價格從 15.00 美元上調至 18.00 美元，並在 11 月 21 日（星期五）的研究報告中給予公司 “表現不佳” 的評級。花旗集團將 Moderna 的目標價格從 30.00 美元下調至 28.00 美元，並在 10 月 23 日（星期四）的研究報告中為公司設定了 “中性” 評級。摩根士丹利在 12 月 12 日（星期五）的報告中將 Moderna 的目標價格從 30.00 美元下調至 28.00 美元，並對該股票設定了 “同等權重” 的評級。最後，Needham &amp; Company LLC 在 10 月 20 日（星期一）的研究報告中重申了對 Moderna 的 “持有” 評級。兩位分析師對該股票給予了買入評級，十二位分析師給予了持有評級，五位分析師給予了賣出評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “減持”，平均目標價格為 29.21 美元。</p>
</div><p><strong>Get Our Latest Analysis on Moderna</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Moderna 的最新分析</strong></p>
</div><h2>Moderna Company Profile</h2>
<div class="lb-trans"><h2>Moderna 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.</p>
<div class="lb-trans"><p>Moderna, Inc.是一家總部位於馬薩諸塞州劍橋的生物技術公司，專注於信使 RNA（mRNA）治療和疫苗。該公司的平台利用合成 mRNA 指示細胞產生可以預防或治療疾病的蛋白質。自 2010 年成立以來，Moderna 已從早期研究發展到一系列旨在應對傳染病、罕見遺傳疾病和慢性疾病的疫苗和治療候選產品。</p>
</div><p>Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.</p>
<div class="lb-trans"><p>Moderna 的旗艦產品是其基於 mRNA 的 COVID-19 疫苗，這是首個獲得緊急使用授權並在多個司法管轄區獲得完全批准的疫苗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Moderna</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>Forget AI, This Will Be the Next Big Tech Breakthrough</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Moderna</li>
<li>請勿刪除，立即閲讀</li>
<li>投資者警報：微型 “3 美元 AI 奇蹟股票” 即將爆發</li>
<li>任何費用可以從資本利得税中扣除嗎？</li>
<li>巴菲特、蓋茨和貝索斯悄悄拋售股票——原因在這裏</li>
<li>忘記 AI，這將是下一個重大科技突破</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJOQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=MRNA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Moderna Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Moderna 嗎？</h2>
</div><p>Before you consider Moderna, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Moderna 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Moderna 並不在名單上。</p>
</div><p>While Moderna currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Moderna 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Corient Private Wealth LLC 持有 Moderna 公司價值 154 萬美元的股票